BETHLEHEM, Pa. -- B. Braun Medical Inc. today announced that it received FDA approval for CefTRIaxONE in the DUPLEX® Drug Delivery System. The availability of CefTRIaxONE, a standard intravenous antibiotic preparation, helps clinicians comply with Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and USP <797> Guidelines that specify medicines should be dispensed in their "most ready-to-use form."
No admixing or thawing is required as each DUPLEX® Drug Delivery System comes complete with drug and diluent in a convenient ready-to-use bag stored at room temperature. With CefTRIaxONE in DUPLEX®, doses can be stored conveniently and are immediately available for emergency IV purposes. B. Braun is proud to have received approval for an additional drug, CefTRIaxONE in the DUPLEX® Drug Delivery System once the current patent expires.
DUPLEX® is a unique closed-system designed to simplify intravenous antibiotic delivery to patients, reduce the risk of medication errors, reduce drug waste and eliminate pharmacy labor required during IV antibiotic delivery preparation.
Features of the DUPLEX® Drug Delivery System for admixing include:
-- Closed system pre-filled with accurate drug and diluent doses in a sealed two-chamber IV bag. No hoods required
-- Caregiver simply squeezes bag to mix the drug and diluent at patient's bedside
--Barcode references final admixture to help ensure correct drug
-- Stores at room temperature
-- PVC-free, DEHP-free, and latex-free
-- Tall man labeling helps to differentiate the drugs in the Duplex Drug
Delivery System
The DUPLEX® System consists of a pre-filled, PVC-free, DEHP-free, and latex-free IV bag containing proper doses of drug and diluent in different compartments separated by a quick release seal. The caregiver simply squeezes the bag to mix the drug and diluent just prior to administration. The DUPLEX® System is equipped with a UCC/EAN-128 barcode that references the final admixture and can be used to reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.
Source: B. Braun
